TOKYO, August 22, 2011 /PRNewswire/ —
Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565),
announces that its wholly owned subsidiary Activus Pharma Co., Ltd.
(“Activus”) is to receive a grant for its “Development of
Innovative Ophthalmic Solutions” from the New Energy and Industrial
Technology Development Organization (NEDO), an Incorporated
Administrative Agency under the Ministry of Economy, Trade and
Industry (METI) as a part of their FY2011 Innovation Promotion
The grant is awarded to private sector companies that focus on
development of advanced technologies with practical application,
and is intended to enhance the global competitiveness of Japanese
companies, as well as to promote development of new industries.
Using Activus Pure Nano-particle Technology (APNT) and
surface-modified nanoparticle technology, Activus is focusing on
development of high value-added products that would solve the
problems existing formulations are facing. To explore the potential
of APNT in treatment of ophthalmic diseases, Activus has signed a
collaboration agreement with Professor Hifofumi Takeuchi
(Pharmaceutical Engineering Laboratory) and Professor Hideaki Hara
(Laboratory of Molecular Pharmacology) of Gifu Pharmaceutical
University and is now working on the development of novel posterior
eye segment medication. Posterior eye segment disease such as
diabetic retinopathy and age-related maculopathy is the primary
cause of blindness and other visual impairments in middle age. An
effective and easy-to-use medication has still not been invented,
and the development of an innovative treatment is anticipated.
Within this subsidized project, Activus will be working on the
development of novel ophthalmic solutions that would differ from
the existing treatments because they would be delivered to the
posterior eye segment. In that way, Activus would contribute to the
QOL improvement in patients with visual impairments.